The Department of Health and Human Services (HHS) and The Centers for Medicare & Medicaid Services (CMS) released the final Notice of Benefit & Payment Parameters for 2020 (the Notice). The Notice contains a change to Code §156.130 – Cost-sharing requirements; specifically, plans are permitted to disregard manufacturer coupons when determining whether a participant has met their out-of-pocket maximum when generic equivalents of the drug are available.

Background

Healthcare reform applies an overall “cost-sharing limit” on essential health benefits under non-grandfathered group health plans. Copays for prescription drugs that qualify as essential health benefits count toward this overall limit. To compete in the market, drug manufacturers often offer coupons to individuals to help defray the cost of their drugs. The Notice expressed concern over this practice. The Notice states the coupons provide incentives to patients and providers to choose more expensive brand-name drugs over more affordable generic options. The updated Code §156.130 – Cost-sharing requirements) includes the following:

“(h) Use of drug manufacturer coupons. For plan years beginning on or after January 1, 2020:

(1) … amounts paid toward cost sharing using any form of direct support offered by drug manufacturers to enrollees to reduce or eliminate immediate out-of-pocket costs for specific prescription brand drugs that have an available and medically appropriate generic equivalent are not required to be counted toward the annual limitation on cost sharing…."

No Available Generic Alternative

The updated rule clarifies that plans can decide to disregard manufacturer coupons for purposes of cost-sharing limitations when a generic alternative is available. However, the rule does not specifically state that plans are required to count coupons toward the out-of-pocket maximum when no generic alternative is available.

Although the updated regulation itself does not specifically state that plans are required to count coupons toward an individual’s out-of-pocket limit when there is no general alternative, language to this effect does appear in the text of the Notice:
“…Where there is no generic equivalent available or medically appropriate… amounts paid toward cost sharing using any form of direct support offered by drug manufacturers must be counted toward the annual limitation on cost sharing…”

Although this text is non-binding, it does illustrate the position taken by HHS: that in cases where no generic alternatives are available, coupons must be counted toward an individual’s out-of-pocket maximum.

Summary

Cost-sharing regulations have been updated to include language that explicitly permits a plan to disregard drug manufacturer coupons when determining whether an individual has met their out-of-pocket maximum. Although the agency does not explicitly state it in the regulations, HHS has been clear about viewing drug manufacturer coupons as counting toward an individual’s out-of-pocket maximum when a generic alternative is not available. Therefore, plan sponsors are advised to discuss this new development with their Pharmacy Benefits Manager, carrier, and/or TPA to determine how to handle drug-manufacturer coupons beginning January 1, 2020.

Please contact your Oswald client team representative for further information.

Oswald Companies | Compliance
Danielle Jarvis | djarvis@oswaldcompanies.com; 216.649.7384
Luke Clark, Sr. Benefits Consultant | lclark@oswaldcompanies.com; 216.367.8758

Disclaimer: Materials are solely for informational purposes as an educational resource. Please contact counsel to obtain advice with respect to any specific issue.